At Investor Conferences


Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in France and Monaco or involving organisations from these countries.

Total search results: 1629 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Blue Heron–Eurofins: investment, 201908 acquisition of Blue Heron Biotech by Eurofins Genomics LLC 2019-08-06
Alizé Pharma–SEVERAL: investment, 201907 financing round Series A €67m of Alizé Pharma 3 led by LSP 2019-07-31
Twist Bioscience–Imagene: nucleic acid storage technology, 201907– supply service DNA encapsulation using DNAshell technology 2019-07-25
Infarco–Keensight Capital: investment, 201907 acquisition of Infarco’s majority stake in 3P Biopharmaceuticals by Keensight 2019-07-23
Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Pyxis Oncology–SEVERAL: investment, 201907 financing round Series A $22m led by Leaps by Bayer 2019-07-17
AM-Pharma–SEVERAL: investment, 201907 financing round €116m co-led by LSP + Andera Partners 2019-07-16
Genmab–Blink Biomedical: therapeutic antibodies, 201907– license to use CD47 Abs in DuoBodies $2.25m upfront + up to $200m per product plus royalties 2019-07-12
Microphyt–CEA Industrie: investment, 201907 financing round totalling €28.5m incl existing + co-investor Supernova Invest 2019-07-11
Microphyt–Demeter: investment, 201907 financing round totalling €28.5m incl existing + co-investor Demeter Partners 2019-07-11
Microphyt–France (govt): investment, 201907 financing round totalling €28.5m incl new + co-lead investor Bpifrance SPI Fund 2019-07-11
Microphyt–Irdi Soridec: investment, 201907 financing round totalling €28.5m incl existing + co-investor Irdi Soridec 2019-07-11
Microphyt–iXO Private Equity: investment, 201907 financing round totalling €28.5m incl new + co-investor iXO Private Equity 2019-07-11
Microphyt–Safilaro: investment, 201907 financing round totalling €28.5m incl new + co-investor Sofilaro 2019-07-11
Microphyt–SEVERAL: investment, 201907 financing round €28.5m co-led by Sofinnova Partners + Bpifrance SPI Fund 2019-07-11
Microphyt–Sofinnova: investment, 201907 financing round totalling €28.5m incl new + co-lead investor Sofinnova Partners 2019-07-11
Nosopharm–Evotec: antibiotics, 201907– collab €na pre-clinical developm of NOSO-502 + 2nd generation odilorhabdin 2019-07-03
Oncovita–Andrew Lloyd Associates: public relations, 201907 service existent by ALA 2019-07-02
Oncovita–Institut Pasteur: cancer immunotherapy, 201907– license excl ww €na for use of oncolytic measles virus platform for product developm + sale 2019-07-02
Oncovita–Institut Pasteur: investment, 201907 existent Institut Pasteur is shareholder of Oncovita 2019-07-02
Sanifit–Andera Partners: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Andera Partners 2019-06-26
Sanifit–la Caixa: investment, 201906 financing round Series D totalling €55.2m incl existing + lead investor Caixa Capital Risc 2019-06-26
Sanifit–SEVERAL: investment, 201906 financing round Series D €55.2m led by Caixa Capital Risc 2019-06-26
Sanifit–SEVERAL: investment, 201906c capitalisation of €17m of convertible bonds 2019-06-26
Vesalius Biocapital–SEVERAL: investment, 201906 final closing of €120m Vesalius Biocapital III fund 2019-06-25
SQZ Biotechnologies–Erytech: drug delivery technology, 201906– license to red blood cell encapsulation from Erytech to develop immunomodulators 2019-06-24
Terns Pharmaceuticals–Genfit: elafibranor, 201906– license excl $35m upfront + $193m milestones + royalties for Greater China 2019-06-24
Sanofi–Alphabet: healthcare informatics, 201906– collab new virtual innovation lab using Google Cloud for future medicines + healthcare services 2019-06-18
Ipsen–Debiopharm: triptorelin, 201906– strategic collab extension 15y developm + prod + distrib Decapeptyl in Europe + certain Asia + Africa 2019-06-12
Medidata Solutions–Dassault Systèmes: investment, 201906– acquisition $5.8b cash tender offer at $92.25/share ANNOUNCED 2019-06-12
Servier–Yposkesi: lentiviral vectors, 201906– collab developm + GMP manufacture of lentiviral vectors for CAR-T cell technology development 2019-06-05
Yukin Therapeutics–Advent France Biotechnology: investment, 201906 financing round totalling €3.3m incl founding + co-lead investor Advent France Bio 2019-06-04
Yukin Therapeutics–Medicxi Ventures: investment, 201906 financing round totalling €3.3m incl new + co-lead investor Medicxi 2019-06-04
Yukin Therapeutics–NewCap: public relations, 201906 service existent by NewCap 2019-06-04
Yukin Therapeutics–SEVERAL: investment, 201906 financing round €3.3m co-led by Advent France Biotechnology + Medicxi 2019-06-04
Domain Therapeutics–BPCE: investment, 201905 investment €3.5m from existing investor Seventure Partners 2019-05-28
Sensorion–Institut Pasteur: gene therapy, 201905– collab framework agreem incl license options for gene therapies for ear diseases 2019-05-27
DNA Script–France (govt): investment, 201905 financing round Series B totalling $38.5m incl new investor Bpifrance Large Venture fund 2019-05-16
DNA Script–Idinvest Partners: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Idinvest Partners 2019-05-16
DNA Script–Illumina: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Illumina Ventures 2019-05-16
DNA Script–Kurma: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Kurma Partners 2019-05-16
DNA Script–Life Sciences Partners: investment, 201905 financing round Series B totalling $38.5m incl new + lead investor LSP 2019-05-16
DNA Script–Merck (DE): investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor M Ventures 2019-05-16
DNA Script–SEVERAL: investment, 201905 financing round Series B $38.5m led by LSP 2019-05-16
DNA Script–Sofinnova: investment, 201905 financing round Series B totalling $38.5m incl existing + co-investor Sofinnova Partners 2019-05-16
TreeFrog Therapeutics–Andrew Lloyd Associates: public relations, 201905 service existent by ALA 2019-05-13
TreeFrog Therapeutics–SEVERAL: investment, 201905 financing round Series A €6.5m led by XAnge + incl Galia Geston et al 2019-05-13
Therachon–Cowen: investment, 201905 existing investor Cowen 2019-05-08
Therachon–France (govt): investment, 201905 existing investors Bpifrance + Inserm Transfert Initiative 2019-05-08
Therachon–Novo Group: investment, 201905 existing investor Novo Holdings 2019-05-08
Therachon–OrbiMed: investment, 201905 existing investor OrbiMed 2019-05-08
Therachon–Pfizer: investment, 201905 existing investor Pfizer Ventures 2019-05-08
Therachon–Pfizer: investment, 201905– acquisition 100% $340m upfront + $470m milestones excl apraglutide development program 2019-05-08
Therachon–Tekla Capital: investment, 201905 existing investor Tekla Capital Management LLC 2019-05-08
Therachon–Versant Ventures: investment, 201905 existing investor Versant Ventures 2019-05-08
AstraZeneca–Transgene: cancer immunotherapy, 201905– collab + license option $10m upfront developm armed oncolytic vaccinia viruses using Invir.IO 2019-05-02
Transgene–Huntsworth: public relations, 201905 service existent by Citigate Dewe Rogerson 2019-05-02
Alentis Therapeutics–Bellevue: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BB Pureos Bioventures 2019-04-30
Alentis Therapeutics–BioMedPartners: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BioMedPartners 2019-04-30
Alentis Therapeutics–France (govt): investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Bpifrance 2019-04-30
Alentis Therapeutics–High-Tech Gründerfonds: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor HTGF 2019-04-30
Alentis Therapeutics–Instinctif Partners: public relations, 201904 service existent media relations by Instinctif 2019-04-30
Alentis Therapeutics–Schroders: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Schroder Adveq 2019-04-30
Alentis Therapeutics–SEVERAL: investment, 201904 financing round Series A CHF12.5m co-led by BioMedPartners + BB Pureos Bioventures 2019-04-30
JnJ–Iktos: drug discovery services, 201904– collab using AI technology for small molecule drug discovery projects Janssen 2019-04-29
Cisbio Bioassays–PerkinElmer: investment, 201904 acquisition by PerkinElmer 2019-04-25
Genecast (CN)–HalioDx: cancer test, 201904– distribution excl of Immunoscore Colon Assay in China by Genecast 2019-04-19
Theranexus–IRISA (FR): bioinformatics, 210904– collab using AI for targeting neuroglial interactions for drug discovery with Dyliss Group 2019-04-09
AgomAb Therapeutics–Advent France Biotechnology: investment, 201904 financing round Series A totalling €21m incl co-lead investor Advent France 2019-04-03
AgomAb Therapeutics–Boehringer: investment, 201904 financing round Series A totalling €21m incl co-investor BIVF 2019-04-03
AgomAb Therapeutics–Omnes Capital: investment, 201904 financing round Series A totalling €21m incl co-investor Omnes 2019-04-03
AgomAb Therapeutics–Pontifax: investment, 201904 financing round Series A totalling €21m incl co-investor Pontifax 2019-04-03
AgomAb Therapeutics–SEVERAL: investment, 201904 financing round Series A €21m co-led by V-Bio Ventures + Advent France Biotechnology 2019-04-03
AgomAb Therapeutics–V-Bio Ventures: investment, 201904 financing round Series A totalling €21m incl co-lead investor V-Bio Ventures 2019-04-03
Karuna–Sofinnova: investment, 201903–201904 financing round Series B totalling $80m incl $12m from new investor Sofinnova Investments 2019-04-01
Cellnovo–NONE: investment, 201903 in administration 2019-03-28
Polyneuron–New Enterprise Associates: investment, 201903 financing round Series A totalling CHF22.5m incl new + co-lead investor NEA 2019-03-28
Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA 2019-03-28
Polyneuron–Sofinnova: investment, 201903 financing round Series A totalling CHF22.5m incl new + lead investor Sofinnova Partners 2019-03-28
H4Orphan Pharma–Cerenis: investment, 201903–201904 excl merger negotations w Cerenis owning 59% of combined company TERMINATED 4/19 2019-03-27
Pierre Fabre–Institut Curie: cancer immunotherapy, 201903– collab extension I-O drug target discovery with IRPF 2019-03-21
Pfizer–Vivet Therapeutics: VTX-801, collab developm €45m (incl acqu 15% share) + €560m milestones (incl acquisition of Vivet) 2019-03-20
Vivet Therapeutics–Pfizer: investment, 201903 acquisition 15% equity interest plus excl option to acquire all outstanding shares 2019-03-20
Merck (DE)–Iktos: drug discovery services, 201903– collab using AI technology for small molecule drug discovery projects 2019-03-14
BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m 2019-03-05
Novasep–Sartorius: chromatography, 201903– collab developm of systems for membrane chromatography SSB 2019-03-05
Anaeropharma Science–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
Humedics–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
MycoTechnology–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
TargEDys–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
TreeFrog Therapeutics–SEVERAL: grant, 201903 non-dilutive funding €600k from Nouvelle-Aquitaine Region + Bpifrance + French Ministry of Research 2019-03-01
Genfit–SEVERAL: investment, 201902–201903 private placement €9m with 500k ordinary shares at €18/share in Europe + outside North America 2019-02-27
Genfit–SEVERAL: investment, 201902–201903 US IPO $125m with 6.15m ADSs at $20.32/ADS at Nasdaq Global Select Market 2019-02-27
Ynsect–SEVERAL: investment, 201902 financing round Series C €110m ($1245m) led by Astanor Ventures 2019-02-21
BiomX–BPCE: investment, 201902 financing round Series B totalling $32m incl existing + co-lead investor Seventure Health for Life Capital fund 2019-02-20
BiomX–SEVERAL: investment, 201902 financing round Series B $32m led by existing investors OrbiMed + JJDC + Takeda Ventures et al 2019-02-20
BPCE–Yucatan: public relations, 201902 service existent media relations for Seventure Parnters in France by Agence Yucatan 2019-02-20
Arvelle Therapeutics–SEVERAL: investment, 201902 financing round Series A $180m with global investor syndicate 2019-02-14
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] – Putting Information into Context 600x60px

» top